

15 April 2025

Botanix Webinar - Tuesday 15 April 2025 – Registration Information

Philadelphia PA and Phoenix AZ, 15 April 2025: Commercial dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), announces that it will be hosting a webinar to provide an update on the Placement referenced in today’s press release and the initial commercial launch of *Sofdra*™.

The webinar will be held today, Tuesday 15 April 2025 @ 11:00am AEST (Sydney/Melbourne)/ 9:00am AWST (Perth). The call will be hosted by Executive Chairman, Vince Ippolito and Chief Executive Officer, Dr Howie McKibbin and Executive Director, Matt Callahan.

Interested participants need to register before the webinar using the link below and dial in details will be sent in return.

Webinar Details

Date:	15 April 2025
Time:	11:00am AEST (Sydney/Melbourne), 9:00am AWST (Perth)
To register:	https://us02web.zoom.us/webinar/register/WN_oeSr-FodSze-pi7aC5fLLQ
Dial in details:	Will be sent to you directly upon registration

Release authorised by the Botanix Board.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.